The Evolution of Targeted Radionuclide Diagnosis of HER2-Positive Breast Cancer

被引:6
|
作者
Bragina, Olga D. [1 ,2 ]
Deyev, Sergei M. [2 ,3 ]
Chernov, Vladimir, I [1 ,2 ]
Tolmachev, Vladimir M. [2 ,4 ]
机构
[1] Russian Acad Sci, Canc Res Inst, Tomsk Natl Res Med Ctr, Tomsk 634009, Russia
[2] Natl Res Tomsk Polytech Univ, Tomsk 634050, Russia
[3] Russian Acad Sci, Shemyakin Ovchinnikov Inst Bioorgan Chem, Moscow 117997, Russia
[4] Uppsala Univ, Uppsala, Sweden
来源
ACTA NATURAE | 2022年 / 14卷 / 02期
关键词
breast cancer; HER2/neu; radionuclide diagnostics; monoclonal antibody; alternative scaffold proteins; HER2; EXPRESSION; THERAPEUTIC TARGETS; RECEPTOR; THERANOSTICS; TRASTUZUMAB; DISCORDANCE; CONCORDANCE; METASTASES; BIOMARKERS; GUIDELINES;
D O I
10.32607/actanaturae.11611
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
This review examines the evolution of the radionuclide diagnosis of HER2-positive breast cancer using various compounds as a targeting module in clinical practice: from full-length antibodies to a new group of small synthetic proteins called alternative scaffold proteins. This topic is of especial relevance today in view of the problems attendant to the detection of breast cancer with HER2/neu overexpression, which, in most cases, introduce errors in the treatment of patients. The results of clinical studies of radiopharmaceuticals based on affibody molecules, ADAPTs, and DARPins for SPECT and PET have demonstrated good tolerability of the compounds, their rapid excretion from the body, and the possibility to differentiate tumor sites depending on the HER2/neu status. This indicates that targeted radionuclide diagnosis holds promise and the need to continue research in this direction.
引用
收藏
页码:4 / 15
页数:12
相关论文
共 50 条
  • [31] Recent advances in targeted therapies in the treatment of HER2-positive metastatic breast cancer
    Ismaili, Nabil
    Belbaraka, Rhizlane
    Elomrani, Abdelhamid
    Khouchani, Mouna
    Tahri, Ali
    PRESSE MEDICALE, 2013, 42 (11): : 1461 - 1468
  • [32] Targeted Agents for HER2-Positive Breast Cancer: Optimal Use in Older Patients
    Jasmeet Chadha Singh
    Stuart M. Lichtman
    Drugs & Aging, 2015, 32 : 975 - 982
  • [33] Targeted Agents for HER2-Positive Breast Cancer: Optimal Use in Older Patients
    Singh, Jasmeet Chadha
    Lichtman, Stuart M.
    DRUGS & AGING, 2015, 32 (12) : 975 - 982
  • [34] Combination of radiotherapy and targeted therapy for HER2-positive breast cancer brain metastases
    Xiaojing Yang
    Hanru Ren
    Yi Xu
    Xue Peng
    Wenxi Yu
    Zan Shen
    European Journal of Medical Research, 28
  • [35] Targeted Agents for HER2-Positive Breast Cancer: Optimal Use in Older Patients
    Jasmeet Chadha Singh
    Stuart M. Lichtman
    Drugs & Aging, 2021, 38 : 829 - 844
  • [36] The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer
    Véronique Diéras
    Thomas Bachelot
    Targeted Oncology, 2014, 9 : 111 - 122
  • [37] Targeted Agents for HER2-Positive Breast Cancer: Optimal Use in Older Patients
    Singh, Jasmeet Chadha
    Lichtman, Stuart M.
    DRUGS & AGING, 2021, 38 (10) : 829 - 844
  • [38] Immunotherapies against HER2-Positive Breast Cancer
    Duro-Sanchez, Santiago
    Alonso, Macarena Roman
    Arribas, Joaquin
    CANCERS, 2023, 15 (04)
  • [39] Hereditary component of HER2-positive breast cancer
    Iglesias Campos, M.
    Jimena Marquez, A.
    Peralta Linero, R. J.
    Alba Conejo, E.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1325 - S1325
  • [40] Progression and treatment of HER2-positive breast cancer
    April Davoli
    Barbara A. Hocevar
    Thomas L. Brown
    Cancer Chemotherapy and Pharmacology, 2010, 65 : 611 - 623